Search
During his recent visit to Tianjin, Li Li, Director of the National Medical Products Administration, emphasized the paramount importance of reforming drug and medical device regulations to enhance the efficiency of research and development (R&D) innovation. He advocated for bolstering services through various initiatives, including "early intervention, tailored policies for each enterprise, comprehensive process guidance, and the integration of research and review processes." Li Li also advocated for the wider adoption of pilot project experiences, with the aim of expediting the review and approval process. Additionally, he encouraged the execution of international multi-center clinical trials, fostering a synchronized environment for the R&D, application, review, and market launch of global innovative drugs and medical devices within China.
-
C114 Communication Network -
Communication Home
